The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.
Human Growth Hormone and Human Aging
Abstract
UNTIL recently, there has been little scientific inquiry into the physiological significance of, and possible therapy for, GH deficiency in adulthood. This was because the lack of efficacy in humans of animal-derived (e.g.1 bovine or porcine) GH and the limited supply of human cadaveric GH restricted use of exogenous GH to treatment of GHdeficient children. The availability of recombinant human GH (rhGH) has led to a renewal of scientific and clinical interest in investigating wider indications for GH administration. It is now recognized that GH deficiency may exert adverse metabolic effects in adults with panhypopituitarism, and that these effects can be reversed or attenuated by treatment with rhGH (1, 2). Recently, it has also become apparent that, with advancing age, an increasing proportion of men and women with no clinical evidence of pituitary pathology show decreases in GH secretion and serum levels of insulin-like growth factor-I (IGF-I) (3, 4). Because GH deficiency (1, 2) and normal aging (5) are both associated with decreases in protein synthesis and percent of lean body and bone mass, and with increases in percent of body fat, it is possible that reduced GH secretion and IGF-I levels might account, at least in part, for one or more of the above effects of aging, and that some older people might benefit from treatment with rhGH. In this regard, in several recent studies, administration of rhGH for periods varying from a few weeks to 6 months has resulted in improvements in nitrogen balance, an increase in lean body mass, and a decrease in percent body fat in older persons with low IGF-I levels (3, 4, 6, 7). We review herein the published work describing the alterations in GH and IGF-I production with increasing age, and the methods, benefits, and risks of GH treatment of older persons in the light of new knowledge regarding basic physiology of GH secretion and action. We also attempt to point out areas requiring further investigations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Like GH, serum IGF-1 increases with age until puberty, and then gradually declines into old age (Figure 1C).61, 65”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [61]
In the citing paper
“The magnitude of GH pulses peak during puberty and subsequently decline at a gradual rate of approximately 1-2% per year until death in men and women.59-61”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [61]
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R. C., LING, N. C., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,536
Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex
de Vos, A. M., Ultsch, M. H., & Kossiakoff, A. A. (1992) · Science · doi:10.1126/science.1549776 · Cited by 2,237
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Riggs, B. L., Wahner, H. W., Dunn, W. L., Mazess, R. B., Offord, K. P., & Melton, L. J. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110039 · Cited by 1,194
D’Ercole, A. J., Stiles, A. D., & Underwood, L. E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.3.935 · Cited by 1,179
BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebæk, N. E., & Christiansen, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92328-3 · Cited by 889
Berelowitz, M., Szabó, M., Frohman, L. A., Firestone, S. L., Chu, L., & Hintz, R. L. (1981) · Science · doi:10.1126/science.6262917 · Cited by 829
Daughaday, W. H., MARIZ, I. K., & Blethen, S. L. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-4-781 · Cited by 733
An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I.
ELGIN, R. G., Busby, W. H., & Clemmons, D. R. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3254 · Cited by 685
Cited by
Sorted by citations
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Conrad, P. (2007) · Johns Hopkins University Press eBooks · doi:10.56021/9780801885846 · Cited by 1,448
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
Riggs, B. L., Khosla, S., & Melton, L. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.5.763 · Cited by 1,161
Metadata
- Authors
- CORPAS, E., HARMAN, S. M., & BLACKMAN, M. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- HARMAN, S. MITCHELL
- ORCID
- HARMAN, S. MITCHELL
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1993-02
- Volume
- 14
- Issue
- 1
- Pages
- 20-39
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W1964005327
- Cited by
- 911
- References
- 260
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 12 · 2020: 19 · 2019: 16 · 2018: 14 · 2017: 16 · 2016: 11 · 2015: 19 · 2014: 18 · 2013: 18 · 2012: 24
- FWCI
- 26.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- human growth hormone, aging, recombinant human growth hormone, growth hormone deficiency, insulin-like growth factor I, older adults, lean body mass, fat mass, nitrogen balance, growth hormone secretion, panhypopituitarism, growth hormone therapy
- MeSH terms
- Adult, Aging, Animals, Humans, Immune System, Insulin-Like Growth Factor I, Receptors, Somatotropin, Risk Factors, Growth Hormone, Growth Hormone-Releasing Hormone, Receptor, IGF Type 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
